University of Notre Dame researchers have discovered a compound that accelerates diabetic wound healing, which may open the door to new treatment strategies. Non-healing chronic wounds are a major complication of diabetes, which result in more than 70,000 lower-limb amputations in the United States alone each year.

In a new study published today in Nature Structural and Molecular Biology, scientists from the University of Surrey have uncovered a collection of important proteins that carry out and regulate critical biological processes. As the malfunctioning of these proteins and processes are linked to diseases such as cancer, their findings could help with the development of more effective therapies for treating incurable and debilitating illnesses.

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients. The researchers from the University of Birmingham believe that the findings present the possibility of new therapies for patients with non-alcoholic fatty liver disease, for which there is no current licensed treatment.

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

Despite legal and ethical requirements, information on clinical trials for drugs approved by the U.S. Food and Drug Administration (FDA) varied widely among some of the world's largest drug companies, according to a new study led by a researcher at NYU Langone Medical Center's Division of Medical Ethics in the Department of Population Health.

Years of research in University of Illinois scientist John Erdman's laboratory have demonstrated that lycopene, the bioactive red pigment found in tomatoes, reduces growth of prostate tumors in a variety of animal models. Until now, though, he did not have a way to trace lycopene's metabolism in the human body.

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure. The findings, from a large clinical trial known as EMPA-REG OUTCOME, were presented by Yale professor of medicine and clinical chief of endocrinology, Dr. Silvio E. Inzucchi, at the 2015 American Heart Association (AHA) Scientific Session in Orlando, Florida on Nov. 9.